Vlad Coric (Getty Images)
Biohaven's reformulated ALS drug is a flop in anxiety, unnerving investors ahead of CGRP migraine decision
Weeks after raising investors’ hopes around a reformulated ALS generic as a treatment for Alzheimer’s, Biohaven said the drug is a flop in generalized …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
